Products from BPS Bioscience require a minimum order value above 400€
Application: Use as positive control in the development of anti-CD22 CAR-T cells.Screen modulators of anti-CD22 CAR-T cytotoxicity.Design and optimize co-culture cytotoxicity assays for anti-CD22 specific CAR-T cell evaluation.
Background: CD22, also known as Siglec-2, is a nearly universally expressed B cell surface antigen. It is reported to act as an inhibitory co-receptor of the B cell receptor to control the body’s B cell response. In 2017 the FDA approved inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate targeting CD22, for patients with B cell acute lymphoblastic leukemia (ALL). Outcomes are poor for patients with large B-cell lymphoma who relapse after CD19-targeted therapy. However, CD22 CAR-T cells have demonstrated high efficacy in pediatric and adult B-ALL in clinical trials, providing a therapeutic option for patients with CD22+ malignancies who show disease progression after CD19-directed chimeric antigen receptor (CAR) T cell therapy.
Description: The Anti-CD22 CAR-T Cells are produced by high-titer lentiviral transduction of human primary CD4+and CD8+ T cells using the Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3ζ) (#78608). These ready-to-use CAR-T cells express an anti-CD22 CAR consisting of the ScFv (Single chain fragment variable) of anti-CD22(clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1).These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.Figure 1. Construct diagram showing components of the anti-CD22 CAR expressed in Anti-CD22 CAR-T Cells.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Supplied As: Each vial contains 2 x 106 cells in 1 ml of CryoStor® CS10 (Stemcell Technologies #100-1061)
Target: CD22
Uniprot: P20273
Warnings: Avoid freeze/thaw cyclesDonors have been screened and determined negative for:Hepatitis B (anti-HBc EIA, HBsAg EIA)Hepatitis C (anti-HCV EIA)Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)Human T-Lymphotropic Virus (HTLV-I/II)HIV-1/HCV/HBVWest Nile VirusTrypanasoma cruziNote: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate Biological Safety Level 2 (BSL-2) precautions should be used.
Biosafety Level: BSL-1
References: Schultz L.M., et al., 2024 Leukemia 38(5):963-968.Matthew J.F., et al., 2024 The Lancet 404 (10450): 353-363.
English
Deutsch
